Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Affiliations

• ¹ Research Center of the Centre Hospitalier de l'Université de Montréal, Montréal (CRCHUM), Montreal, Quebec, Canada.
• ² Hematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.
• ³ Department of Oncology, Western University, London, Ontario, Canada.
• ⁴ Lawson Health Research Institute, London, Ontario, Canada.
• ⁵ Lady Davis Institute of the Jewish General Hospital, Segal Cancer Centre, Montreal, Quebec, Canada.
• ⁶ Departments of Oncology and Medicine, McGill University, Montreal, Quebec, Canada.
• ⁷ Department of Microbiology & Immunology, Western University, London, Ontario, Canada.
• ⁸ Canadian Centre for Human Microbiome and Probiotics Research, London, Ontario, Canada.
• ⁹ Peter Brojde Lung Cancer Center, Jewish General Hospital, Montreal, Quebec, Canada.
• ¹⁰ Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, St Mary's Hospital Campus, Imperial College London, London, UK.
• ¹¹ Section of Bioinformatics, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
• ¹² Department of Computational, Cellular and Integrative Biology, University of Trento, Trento, Italy.
• ¹³ Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
• ¹⁴ Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, National Phenome Centre, Imperial College London, London, UK.
• ¹⁵ Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
• ¹⁶ Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Quebec, Canada.
• ¹⁷ Gustave Roussy Cancer Campus, Villejuif, France.
• ¹⁸ Cancer Medicine Department, Gustave Roussy, Villejuif, France.
• ¹⁹ Institut National de la Santé Et et de la Recherche Médicale (INSERM) U1015, ClinicObiome, Equipe Labellisée-28 Ligue Nationale contre le Cancer, Villejuif, France.
• ²⁰ Université Paris-Saclay, Ile-de-France, France.
• ²¹ Department of Medicine, Division of Infectious Diseases, Western University, London, Ontario, Canada.
• ²² Division of Infectious Diseases, St Joseph's Health Care, London, Ontario, Canada.
• ²³ Department of Biochemistry, McGill University, Montréal, Quebec, Canada.
• ²⁴ Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, Quebec, Canada.
• ²⁵ Department of Medicine, Division of Clinical Immunology and Allergy, Western University, London, Ontario, Canada.
• ²⁶ Department of Surgery, Division of General Surgery, Western University, London, Ontario, Canada.
• ²⁷ Departments of Gastroenterology and Hepatology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
• ²⁸ Department of Oncology, Western University, London, Ontario, Canada. saman.malekivareki@lhsc.on.ca.
• ²⁹ Lawson Health Research Institute, London, Ontario, Canada. saman.malekivareki@lhsc.on.ca.
• ³⁰ Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada. saman.malekivareki@lhsc.on.ca.
• ³¹ Department of Medical Biophysics, Western University, London, Ontario, Canada. saman.malekivareki@lhsc.on.ca.
• ³² Ontario Institute of Cancer Research, Toronto, Ontario, Canada. saman.malekivareki@lhsc.on.ca.